Fact checked by Jennifer Klump Breast cancer is the second most common type of cancer in women. While you can’t fully prevent ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

SYNT-101 introduces an innovative method for weight loss by temporarily redirecting nutrient absorption in the small ...

As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% ...

Healthcare and benefits leaders must step up to provide menopausal women with the full-spectrum care they need to protect ...

Obesity is associated with a 35% to 40% increased risk of breast cancer recurrence and death and therefore poorer survival outcomes. This is most clearly established for estrogen receptor–positive ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, T2D and other metabolic diseases.

Roughly 750 people with obesity were randomly split into two ... It stimulates two different gut hormones that affect appetite and blood sugar, while Wegovy primarily affects the action of one.

Recent research reveals how it enhances the expression of key hunger-related receptors and increases sensitivity to leptin, pointing to novel treatments for obesity. Estrogen generated in the brain ...